Aczone Gel 7.5% in the Treatment of Acne Vulgaris in Patients With Skin of Color
Status:
Active, not recruiting
Trial end date:
2021-05-01
Target enrollment:
Participant gender:
Summary
Acne vulgaris is a common skin disease characterized by inflammatory papules, pustules, and
comedones that is prevalent in men and women of color. Research has demonstrated that Aczone
® (dapsone) gel, 7.5% used once daily is effective, safe, and well-tolerated for the
treatment of acne in both men and women; however, limited data is available regarding its
efficacy and safety in skin of color (SOC). The current study aims to investigate the
therapeutic impact of Aczone gel 7.5% in SOC males and females ages 18 and older with acne
vulgaris. The study will also evaluate the impact of Aczone ® gel on hyperpigmentation and
PIH of the face.